News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
30,629 Results
Type
Article (1406)
Company Profile (3)
Press Release (29220)
Section
Business (14798)
Career Advice (95)
Deals (1837)
Drug Delivery (2)
Drug Development (3498)
Employer Resources (1)
FDA (563)
Job Trends (687)
News (19817)
Policy (1007)
Tag
Academia (42)
Adcomms (2)
Allergies (3)
Alliances (1111)
ALS (3)
Alzheimer's disease (40)
Antibody-drug conjugate (ADC) (11)
Approvals (596)
Artificial intelligence (9)
Autoimmune disease (5)
Automation (1)
Bankruptcy (4)
Best Places to Work (618)
Biosimilars (2)
Biotechnology (5)
Bladder cancer (12)
Brain cancer (4)
Breast cancer (27)
Cancer (205)
Cardiovascular disease (17)
Career advice (80)
Career pathing (1)
CAR-T (10)
Cell therapy (26)
Cervical cancer (4)
Clinical research (3124)
Collaboration (29)
Compensation (19)
Complete response letters (2)
COVID-19 (60)
CRISPR (1)
C-suite (15)
Cystic fibrosis (3)
Data (295)
Depression (6)
Diabetes (13)
Diagnostics (245)
Digital health (1)
Drug discovery (9)
Drug pricing (4)
Duchenne muscular dystrophy (11)
Earnings (14098)
Editorial (3)
Employer resources (1)
Events (3039)
Executive appointments (10)
FDA (800)
Frontotemporal dementia (3)
Funding (33)
Gene editing (2)
Gene therapy (12)
GLP-1 (31)
Government (64)
Guidances (152)
Healthcare (692)
IgA nephropathy (3)
Immunology and inflammation (9)
Indications (1)
Infectious disease (74)
Influenza (8)
Intellectual property (6)
Interviews (14)
IPO (1413)
Job creations (96)
Job search strategy (62)
JPM (1)
Labor market (4)
Layoffs (12)
Leadership (1)
Legal (213)
Liver cancer (4)
Lung cancer (29)
Lymphoma (32)
Manufacturing (15)
MASH (9)
Medical device (735)
Medtech (742)
Mergers & acquisitions (446)
Metabolic disorders (31)
Multiple sclerosis (4)
NASH (2)
Neurodegenerative disease (6)
Neuropsychiatric disorders (4)
Neuroscience (66)
NextGen: Class of 2026 (143)
Non-profit (54)
Obesity (11)
Opinion (1)
Ovarian cancer (1)
Pain (7)
Pancreatic cancer (8)
Parkinson's disease (4)
Patents (12)
Patient recruitment (14)
Peanut (3)
People (914)
Pharmaceutical (1)
Phase 1 (788)
Phase 2 (1271)
Phase 3 (1313)
Pipeline (668)
Policy (2)
Postmarket research (202)
Preclinical (289)
Prostate cancer (8)
Radiopharmaceuticals (9)
Rare diseases (27)
Real estate (140)
Recruiting (1)
Regulatory (869)
Reports (3)
Research institute (45)
Resumes & cover letters (20)
RSV (3)
Schizophrenia (1)
Series A (8)
Series B (1)
Sickle cell disease (2)
Special edition (1)
Spinal muscular atrophy (1)
Startups (62)
Stomach cancer (1)
Supply chain (1)
Vaccines (23)
Venture capital (4)
Weight loss (5)
Women's health (3)
Date
Today (11)
Last 7 days (30)
Last 30 days (80)
Last 365 days (1811)
2026 (107)
2025 (1824)
2024 (1923)
2023 (2196)
2022 (2310)
2021 (2454)
2020 (2250)
2019 (1484)
2018 (1217)
2017 (1078)
2016 (726)
2015 (952)
2014 (654)
2013 (311)
2012 (440)
2011 (506)
2010 (486)
Location
Africa (33)
Alabama (5)
Arizona (28)
Arkansas (1)
Asia (2248)
Australia (223)
California (607)
Canada (191)
China (50)
Colorado (34)
Connecticut (30)
Delaware (22)
Europe (3511)
Florida (89)
Georgia (16)
Idaho (1)
Illinois (46)
Indiana (38)
Japan (8)
Kansas (3)
Kentucky (1)
Louisiana (6)
Maine (9)
Maryland (73)
Massachusetts (378)
Michigan (16)
Minnesota (31)
Missouri (14)
Montana (2)
Nevada (20)
New Hampshire (8)
New Jersey (207)
New York (205)
North Carolina (71)
Northern California (293)
Ohio (16)
Oklahoma (1)
Pennsylvania (154)
Rhode Island (2)
South America (32)
Southern California (263)
Tennessee (2)
Texas (127)
United States (2273)
Utah (27)
Virginia (6)
Washington State (53)
Wisconsin (4)
30,629 Results for "106".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
December 17, 2025
·
7 min read
Earnings
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.
February 4, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
October 2, 2025
·
3 min read
Press Releases
SOTIO Presents Positive Results from Non-Human Primate Study of SOT106, a Potential Best-in-Class ADC for Treatment of Sarcoma
November 13, 2025
·
3 min read
Biotech Bay
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced the completion of an oversubscribed $106.6 million Series C financing.
May 13, 2024
·
3 min read
Press Releases
DNA Sequencing Market Size to Hit USD 106.20 Billion by 2034
January 7, 2025
·
1 min read
Press Releases
SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting
March 26, 2025
·
2 min read
Press Releases
SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments
April 29, 2025
·
4 min read
Lone Star Bio
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, provided a preliminary update on recent clinical activity and expected near term milestones for its lead program MB-106 for the treatment of Acute Myeloid Leukemia (AML) following its Fiscal Year 2023 filing with the Securities and Exchange Commission.
March 25, 2024
·
10 min read
Drug Development
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Mustang Bio today announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T-cell therapy, show a favorable safety and efficacy profile in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer.
June 17, 2024
·
6 min read
1 of 3,063
Next
